New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
Ozempic maker’s new weight-loss drug works better, but not quite good enough for analysts
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
